Bridging Balancing Weights and Augmentation in Covariate-adjusted Analyses with Time-to-Event Endpoints: Theory and Practical Recommendations
生存结局协变量调整中平衡加权与增广方法的联系AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要研究随机试验处理效应的协变量调整、加权与增广估计,直接对应因果推断。
生存结局协变量调整中平衡加权与增广方法的联系AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
Covariate adjustment improves the efficiency of treatment-effect analyses in randomized clinical trials, provided the adjustment targets the correct quantity. For time-to-event endpoints, two marginal targets are of primary interest: the log-rank test for the presence of a treatment effect and the marginal hazard ratio for its magnitude. Existing covariate adjustment approaches reach these targets by different ways. Augmentation adjusts the log-rank score by regressing derived outcomes on the baseline covariates within each arm. Weighting instead reweights the two arms to balance the covariates before the survival comparison is formed: inverse probability weighting does so through a fitted propensity model, while calibration weighting solves directly for weights that match covariate means. In this manuscript, we first develop balancing weighting for time-to-event endpoints, covering both calibration weights (stable balancing weights and entropy balancing) and propensity score weights, and prove that any balancing-regular weighting is first-order equivalent to the augmented log-rank score and to the root of the marginal Cox score. All three routes therefore deliver the same estimator to first order, and calibration reaches it without fitting any model. The weighted procedures thereby inherit the validity and guaranteed efficiency gain of the augmentation approach. In addition, we show that the efficiency gain grows with the prognostic strength of the adjustment covariates, while the practical caveat lies in variance estimation, for which we give recommendations to guard against finite-sample Type I error inflation. We further confirm our results through simulation studies and an analysis of the REWIND cardiovascular trial.